Nicotine abuse vaccine - Biota Pharmaceuticals

Drug Profile

Nicotine abuse vaccine - Biota Pharmaceuticals

Alternative Names: 3'-aminomethyl-Nic r-EPA Conjugate; Nicotine conjugate vaccine - Nabi Biopharmaceuticals; NicVAX

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer Aktiv-Dry; Aviragen Therapeutics; Nabi Biopharmaceuticals
  • Class Drug withdrawal therapies; Smoking cessation therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Smoking withdrawal
  • New Molecular Entity No

Highest Development Phases

  • Suspended Smoking withdrawal

Most Recent Events

  • 08 Nov 2012 Biota Holdings has merged with Nabi Biopharmaceuticals to form Biota Pharmaceuticals
  • 17 Oct 2012 Efficacy and adverse events data from a phase II trial in Smoking withdrawal reported by Nabi Biopharmaceuticals
  • 11 May 2012 Nabi Biopharmaceuticals completes a phase III trial in Smoking withdrawal in USA (NCT01375933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top